Unleash the Power of RNAa
Learn More >
Activating Genes to Combat Disease
Learn More >
We are an clinical-stage pharmaceutical company creating first-in-class therapies designed to boost expression of therapeutic genes in diseased cells.
RNAa (RNA activation) is a platform technology to selectively turn genes on by using short duplex RNA known as small activating RNA (saRNA).
RNAa is among the limited technologies capable of stimulating the production of targeted endogenous genes.
Ractigen has a diverse pipeline covering previously undruggable diseases and monogenic disorders including oncology, neurological and neuromuscular disorders, and liver-related indications.
The pipeline explores the boundaries of our technology and pushes for the next generation of RNAa therapeutics.
Our leadership comprises a unified team of experts in RNA research and drug development, including the pioneers of RNAa technology, specialists in nucleic acid chemistry, biotech entrepreneurs, and authorities in drug discovery.